Idera’s tilsotolimod shows positive effect in mid-stage melanoma study

Source: Seeking Alpha, April 2020

  • Idera Pharmaceuticals (IDRA -2.4%) announces final results from a Phase 1/2 clinical trial, ILLUMINATE-204, evaluating Toll-like receptor 9 (TLR9) agonist tilsotolimod, combined with Bristol-Myers Squibb’s (BMY -1.4%) Yervoy (ipilimumab), in metastatic melanoma patients.
  • In 49 evaluable subjects, the overall response rate was 22.4% (n=11/49), including two complete responders. 24 participants showed stable cancer implying a disease control rate of 71.4% (n=35/49).
  • Median overall survival (OS) was 21.0 months.
READ THE ORIGINAL FULL ARTICLE